Cardiovasc Diabetol. 2025 May 14;24(1):208. doi: 10.1186/s12933-025-02767-9.ABSTRACTThe rising prevalence of Type 2 diabetes (T2D) has been closely associated with an increased incidence of cardiovascular diseases, particularly heart failure with preserved ejection fraction (HFpEF). Cardiometabolic
Cardiovasc Diabetol. 2025 May 14;24(1):207. doi: 10.1186/s12933-025-02722-8.ABSTRACTBACKGROUND: Existing evidence suggests that elevated 1-hour post-load plasma glucose (1-h PG ≥ 8.6 mmol/L) during an oral glucose tolerance test (OGTT) is associated with atherogenic lipid parameters which are linked
Cardiovasc Diabetol. 2025 May 14;24(1):205. doi: 10.1186/s12933-025-02739-z.ABSTRACTBACKGROUND: Gestational diabetes mellitus (GDM) affects 2-20% of pregnant women worldwide and is linked to fetal overgrowth, increased perinatal morbidity, and mortality, as well as a higher risk of developing cardio
Cardiovasc Diabetol. 2025 May 14;24(1):210. doi: 10.1186/s12933-025-02747-z.ABSTRACTBACKGROUND: Maintaining optimal glucose control is critical for postoperative care cardiac surgery patients. Continuous glucose monitoring (CGM) in this setting remains understudied. We evaluated the efficacy of CGM
Cardiovasc Diabetol. 2025 May 14;24(1):211. doi: 10.1186/s12933-025-02734-4.ABSTRACTBACKGROUND: Type 2 diabetes mellitus (T2DM) represents a significant risk factor for cardiovascular disease, particularly heart failure with preserved ejection fraction (HFpEF). HFpEF predominantly affects elderly in
Cardiovasc Diabetol. 2025 May 13;24(1):203. doi: 10.1186/s12933-025-02748-y.ABSTRACTBACKGROUND: Patients diagnosed with both aortic stenosis (AS) and diabetes mellitus (DM) encounter a distinctive set of challenges due to the interplay between these two conditions. This study aimed to investigate th
Cardiovasc Diabetol. 2025 May 12;24(1):201. doi: 10.1186/s12933-025-02738-0.ABSTRACTBACKGROUND: Heart failure with preserved ejection fraction (HFpEF) is an increasingly prevalent clinical syndrome with high morbidity and mortality. Although HFpEF frequently coexists with cardiometabolic diseases, t
Cardiovasc Diabetol. 2025 May 9;24(1):198. doi: 10.1186/s12933-025-02761-1.ABSTRACTBACKGROUND: Insulin resistance and central obesity are major risk factors for cardiometabolic diseases. The triglyceride-glucose index (TyG) and lipid accumulation product (LAP) are markers that independently predict
Cardiovasc Diabetol. 2025 May 9;24(1):199. doi: 10.1186/s12933-025-02762-0.ABSTRACTBACKGROUND: Stress hyperglycemia ratio (SHR) and glycemic variability (GV) reflect acute glucose elevation and fluctuations, which correlate with adverse outcomes in patients with atherosclerotic cardiovascular diseas
Cardiovasc Diabetol. 2025 May 9;24(1):196. doi: 10.1186/s12933-025-02756-y.ABSTRACTBACKGROUND: Clinical trials have established the prognostic benefits of sodium‒glucose cotransporter 2 (SGLT2) inhibitors in patients with type 2 diabetes mellitus (T2DM) and heart failure (HF) with preserved ejection
Cardiovasc Diabetol. 2025 May 9;24(1):195. doi: 10.1186/s12933-025-02746-0.ABSTRACTBACKGROUND: Gestational diabetes mellitus (GDM), characterized by insulin resistance (IR) and β-cell dysfunction, is one of the most common complications of pregnancy with unmet needs of prevention methods.OBJECTIVE:
Cardiovasc Diabetol. 2025 May 6;24(1):194. doi: 10.1186/s12933-025-02753-1.ABSTRACTBACKGROUND: Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs) are both recommended as first-line antihypertensive agents for patients with diabetes. While pharmacological mec
Cardiovasc Diabetol. 2025 May 3;24(1):192. doi: 10.1186/s12933-025-02720-w.ABSTRACTBACKGROUND AND PURPOSE: Epicardial adipose tissue (EAT) comprises three distinct lipid components, each exerting differential effects on cardiovascular diseases. During disease progression, dynamic alterations in lipi
Cardiovasc Diabetol. 2025 May 3;24(1):193. doi: 10.1186/s12933-025-02736-2.ABSTRACTBACKGROUND: Obesity and insulin resistance are well-established risk factors for atherosclerosis and cardiovascular disease (CVD). Although some obesity- and insulin resistance-related indices (OIRIs) have been linked
No abstractCardiovasc Diabetol. 2025 May 3;24(1):191. doi: 10.1186/s12933-025-02727-3.NO ABSTRACTPMID:40319276 | PMC:PMC12049788 | DOI:10.1186/s12933-025-02727-3
Cardiovasc Diabetol. 2025 May 2;24(1):189. doi: 10.1186/s12933-025-02744-2.ABSTRACTBACKGROUND: Early identification of individuals at risk for gestational diabetes mellitus (GDM) is essential for mitigating its adverse effects on both maternal and foetal health. This study aimed to evaluate the pred
Cardiovasc Diabetol. 2025 May 2;24(1):190. doi: 10.1186/s12933-025-02745-1.ABSTRACTBACKGROUND: Sodium-glucose co-transporter 2 (SGLT2) inhibitors are important for treating patients with preserved left ventricular (LV) ejection fraction (LVEF). Several studies have assessed the effects of SGLT2 inhi
Cardiovasc Diabetol. 2025 May 2;24(1):188. doi: 10.1186/s12933-025-02751-3.ABSTRACTStress-induced hyperglycemia (SIH) is a physiological response to acute or chronic stress characterized by elevated blood glucose levels. It is prevalent in both patients with and without diabetes, particularly those
Cardiovasc Diabetol. 2025 May 2;24(1):187. doi: 10.1186/s12933-025-02700-0.ABSTRACTThe 10th Cardiovascular Outcome Trial (CVOT) Summit: Congress on Cardiovascular, Kidney, and Metabolic Outcomes was held virtually on December 5-6, 2024. This year, discussions about cardiovascular (CV) and kidney out
Cardiovasc Diabetol. 2025 Apr 28;24(1):186. doi: 10.1186/s12933-025-02750-4.ABSTRACTAs a heterogeneous syndrome, heart failure with preserved ejection fraction (HFpEF) has become the leading form of heart failure worldwide. Increasing evidence has identified that diabetes mellitus (DM) increases the
Cardiovasc Diabetol. 2025 Apr 26;24(1):184. doi: 10.1186/s12933-025-02743-3.ABSTRACTBACKGROUND: Acute hyperglycemia on admission is frequently observed during the early phase after acute myocardial infarction (MI), even without the history of diabetes mellitus. We previously reported that inhibiting
Cardiovasc Diabetol. 2025 Apr 26;24(1):185. doi: 10.1186/s12933-025-02678-9.ABSTRACTIMPORTANCE: Although sodium‒glucose cotransporter-2 (SGLT2) inhibitors have cardiorenal benefits, their efficacy in patients with type 2 diabetes mellitus (T2DM) and chronic coronary syndrome (CCS) undergoing percuta
Cardiovasc Diabetol. 2025 Apr 24;24(1):178. doi: 10.1186/s12933-025-02740-6.ABSTRACTBACKGROUND: Vasculopathy is the most prevalent complication of diabetes. Endothelial damage, a primary contributor to hyperglycemic vascular complications, impacts macro- and micro-vasculatures, causing functional im
Cardiovasc Diabetol. 2025 Apr 24;24(1):177. doi: 10.1186/s12933-025-02737-1.ABSTRACTBACKGROUND: Guidelines recommend combination therapy with glucagonlike peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter 2 inhibitors (SGLT2is) for cardiorenal risk reduction in people with type
